Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
81643-9270-01 81643-9270 Floxuridine Floxuridine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intra-arterial June 9, 2022 In Use
00054-4550-15 00054-4550 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 1, 1994 May 31, 2025 In Use
00054-4550-25 00054-4550 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 1, 1994 In Use
00378-3547-25 00378-3547 Mercaptopurine Mercaptopurine 50.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral July 1, 2005 June 30, 2025 In Use
00378-3547-52 00378-3547 Mercaptopurine Mercaptopurine 50.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral July 1, 2005 In Use
00013-0132-02 00013-0132 Estramustine Phosphate Sodium Emcyt 140.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Jan. 1, 1992 Sept. 30, 2024 In Use
00054-8550-25 00054-8550 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 1, 1994 Aug. 31, 2024 In Use
00069-3033-20 00069-3033 Doxorubicin Hydrochloride Doxorubicin Hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 23, 1987 July 31, 2024 In Use
00517-4300-01 00517-4300 Paclitaxel PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous May 2, 2023 In Use
45963-0611-53 45963-0611 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 5, 2015 Nov. 30, 2023 In Use
45963-0611-59 45963-0611 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Jan. 5, 2015 Aug. 31, 2024 In Use
47781-0200-50 47781-0200 Melphalan USP, 2 mg Melphalan 2.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral March 22, 2017 May 1, 2024 In Use
50242-0623-42 50242-0623 ENTRECTINIB Rozlytrek 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Oral Oct. 20, 2023 In Use
51079-0670-01 51079-0670 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral July 13, 1995 In Use
51079-0670-05 51079-0670 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral July 13, 1995 In Use
51990-0201-06 51990-0201 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC,CRAF, BRAF Oral Dec. 1, 2022 In Use
51990-0201-12 51990-0201 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC,CRAF, BRAF Oral Dec. 1, 2022 In Use
55292-0811-55 55292-0811 Dactinomycin Cosmegen 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Dec. 10, 1964 Nov. 30, 2024 In Use
59148-0046-70 59148-0046 Decitabine Dacogen 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 2, 2006 Aug. 31, 2024 In Use
60505-6065-00 60505-6065 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6066-00 60505-6066 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6067-00 60505-6067 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6068-00 60505-6068 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6271-01 60505-6271 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jan. 23, 2024 In Use
63629-9530-01 63629-9530 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 12, 2022 April 30, 2024 In Use
63629-9531-01 63629-9531 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Dec. 22, 2022 April 30, 2024 In Use
66993-0489-35 66993-0489 Dactinomycin Dactinomycin 0.5 mg/mL Chemotherapy Antitumor Antibiotic Carboxylic Acids and Amino Acids/Peptides Intravenous Dec. 4, 2017 Nov. 30, 2024 In Use
69656-0103-30 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2018 Aug. 31, 2024 In Use
69656-0103-61 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral July 1, 2020 Aug. 31, 2024 In Use
69656-0103-90 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral March 27, 2017 May 31, 2022 In Use
69660-0201-91 69660-0201 Rucaparib Rubraca 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 Dec. 31, 2025 In Use
69660-0202-91 69660-0202 Rucaparib Rubraca 250.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral May 1, 2017 July 31, 2025 In Use
69660-0203-91 69660-0203 Rucaparib Rubraca 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 July 31, 2025 In Use
70437-0240-18 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral July 17, 2017 In Use
70437-0240-26 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral July 17, 2017 In Use
70437-0240-33 70437-0240 Neratinib Nerlynx 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral July 17, 2017 In Use
70860-0200-05 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 Dec. 31, 2024 In Use
70860-0200-17 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 Nov. 30, 2024 In Use
70860-0200-50 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 Dec. 31, 2024 In Use
70860-0205-50 70860-0205 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous July 31, 2017 March 31, 2024 In Use
70860-0215-66 70860-0215 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Dec. 15, 2021 Sept. 30, 2024 In Use
70860-0215-67 70860-0215 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Dec. 15, 2021 Nov. 30, 2024 In Use
70860-0215-68 70860-0215 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Nov. 30, 2019 April 30, 2024 In Use
70860-0217-10 70860-0217 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 30, 2020 Oct. 31, 2024 In Use
70860-0218-03 70860-0218 Cyclophosphamide Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 11, 2020 Oct. 31, 2024 In Use
70860-0218-05 70860-0218 Cyclophosphamide Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 11, 2020 Oct. 31, 2024 In Use
70860-0218-10 70860-0218 Cyclophosphamide Cyclophosphamide 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 21, 2021 Aug. 31, 2024 In Use
70860-0219-20 70860-0219 decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 15, 2021 Dec. 31, 2024 In Use
70860-0223-61 70860-0223 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous July 11, 2022 April 30, 2024 In Use
72730-0111-01 72730-0111 infigratinib TRUSELTIQ 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR Oral May 28, 2021 In Use

Found 10,000 results in 9 milliseconds — Export these results